ZUMA-1五年随访支持阿基仑赛在难治性大B细胞淋巴瘤中的治愈潜力
ZUMA-1是一项单臂、多中心、注册性2期试验,评估阿基仑赛(axi-cel)自体抗CD19 CAR T细胞疗法在难治性大B细胞淋巴瘤中的疗效。5年随访显示,101例患者客观缓解率83%(完全缓解率58%),中位随访63.1个月时31%患者缓解持续;中位总生存25.8个月,估计5年总生存率42.6%,5年疾病特异性生存率51.0%;未观察到新的严重不良事件或与axi-cel相关的死亡。
要点
- 101例可评估患者客观缓解率83%,完全缓解率58%,中位随访63.1个月时31%缓解持续。
- 中位总生存25.8个月,估计5年总生存率42.6%,5年疾病特异性生存率51.0%。
- 额外随访未观察到新的严重不良事件或与axi-cel相关的死亡。
核心结论
- ZUMA-1的5年随访分析显示难治性大B细胞淋巴瘤患者总生存和疾病特异性生存持续,未出现新的安全性信号。
- 持久缓解不要求长期B细胞缺乏,这些发现支持axi-cel在部分侵袭性B细胞淋巴瘤患者中的治愈潜力。
研究设计与样本
- ZUMA-1为单臂、多中心、注册性2期试验,纳入符合条件的成人患者,接受淋巴细胞清除性化疗后输注axi-cel(2×10^6个细胞/kg)。
- 在已接受治疗的患者中评估研究者评估的缓解、生存、安全性和药代动力学,共101例患者。
主要发现
- 101例患者客观缓解率为83%(完全缓解率58%);中位随访63.1个月,数据截止时31%患者缓解持续。
- 中位总生存为25.8个月,估计5年总生存率为42.6%;估计5年疾病特异性生存率(排除与疾病进展无关的死亡)为51.0%。
- 额外随访后未观察到新的严重不良事件或与axi-cel相关的死亡。
- 3年时可评估患者外周血B细胞均可检测到,91%患者出现多克隆B细胞恢复;60个月时持续缓解与早期CAR T细胞扩增相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we assessed outcomes in ZUMA-1 after 5 years of follow-up. Eligible adults received lymphodepleting chemotherapy followed by axi-cel (2 × 106 cells per kg). Investigator-assessed response, survival, safety, and pharmacokinetics were assessed in patients who had received treatment. The objective response rate in these 101 patients was 83% (58% complete response rate); with a median follow-up of 63.1 months, responses were ongoing in 31% of patients at data cutoff. Median overall survival (OS) was 25.8 months, and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91% of patients. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. This trial was registered at ClinicalTrials.gov, as #NCT02348216.
引用
- Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023. PMID: 36821768. doi:10.1182/blood.2022018893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。